T 0994/12 () of 24.2.2015

European Case Law Identifier: ECLI:EP:BA:2015:T099412.20150224
Date of decision: 24 February 2015
Case number: T 0994/12
Application number: 07102856.7
IPC class: A61K 9/08
A61K 9/19
A61K 47/10
A61K 47/18
A61K 31/335
A61K 31/365
Language of proceedings: EN
Distribution: D
Download and more information:
Decision text in EN (PDF, 227 KB)
Documentation of the appeal procedure can be found in the Register
Bibliographic information is available in: EN
Versions: Unpublished
Title of application: Pharmaceutical formulations for parenteral administration comprising epothilone
Applicant name: Novartis AG
Novartis Pharma GmbH
Opponent name: Bristol-Myers Squibb Company
Bayer Pharma Aktiengesellschaft
Board: 3.3.07
Headnote: -
Relevant legal provisions:
European Patent Convention Art 113(2)
European Patent Convention Art 101
Keywords: Basis of decision - text or agreement to text withdrawn by patent proprietor
Basis of decision - patent revoked


Cited decisions:
T 0073/84
Citing decisions:

Summary of Facts and Submissions

I. An appeal was lodged by opponent 1 (appellant) against the decision of the opposition division announced at the oral proceedings on 25 November 2011 concerning maintenance of European Patent No. 1 800 664 in amended form.

II. The appellant requested that the decision under appeal be set aside and the European patent be revoked.

III. With letter of 12 February 2015 the patent proprietors (respondents) filed the following declaration:

"The Proprietor hereby withdraws its approval of the text of the patent as granted and as upheld by the Opposition Division including the Auxiliary Requests submitted. As there is no approved text, the Proprietor understands that this withdrawal will have the consequence that the patent will be revoked (see e.g. T 1526/06).

The Proprietor understands that oral proceedings will no longer be necessary".

IV. The oral proceedings which had been arranged for 8 May 2015 were thereafter cancelled.

Reasons for the Decision

1. Under Article 113(2) EPC the European Patent Office must consider and decide upon the European patent only in the text submitted to it, or agreed, by the proprietor of the patent. This principle is part of the common provisions governing procedure and is therefore to be strictly observed also in opposition and opposition appeal proceedings.

2. In the present case the respondents withdrew during the appeal proceedings their approval of the text of the patent as granted and as upheld by the opposition division, including all the auxiliary requests submitted, with the consequence that there is no text of the patent on the basis of which the Board can consider the case. With the same letter the respondents themselves envisaged revocation of the patent as the consequence of this withdrawal.

3. While the procedure for revocation pursuant to Articles 105a to 105c EPC is not available during opposition and opposition appeal proceedings, it is the consistent approach of the case law that, if the patent proprietor states that he no longer approves the text in which the patent was granted and does not submit or withdraws any amended text, the patent as a consequence of Article 113(2) EPC is to be revoked without substantive examination as to patentability, which becomes impossible in the absence of a valid text (see Case Law of the Boards of Appeal of the EPO, 7th edition 2013, IV.C.5.2, in particular T 73/84, OJ EPO 1985, 241 and the numerous decisions following the same approach).

4. The Board has no reason in the present case to deviate from the consistent approach of the case law, with the consequence that the patent is to be revoked.


For these reasons it is decided that:

1. The decision under appeal is set aside.

2. The patent is revoked.

Quick Navigation